PMGC Holdings Inc. 8-K

What Happened

• PMGC Holdings Inc. (through its wholly owned subsidiary Northstrive Biosciences Inc.) announced a Third Amendment to a License Agreement with MOA Life Plus Co., Ltd., effective March 24, 2026.
• The amendment updates and replaces Exhibit C of the original April 30, 2024 License Agreement to revise milestone definitions and timelines for the licensed Field, including pre-clinical phases and events tied to Investigational New Drug (IND) applications.
• The Company also agreed to pay MOA a monetary consideration upon execution and within 30 days after the March 24, 2026 effective date.

Key Details

• Parties: Northstrive Biosciences Inc. (PMGC subsidiary) and MOA Life Plus Co., Ltd. (Republic of Korea).
• Effective Date: March 24, 2026; 8-K filed March 27, 2026.
• Scope: Exhibit C of the original License Agreement was amended and restated in its entirety to update milestone timing and specific pre-clinical/IND-related milestones.
• Payment: PMGC will pay MOA a monetary consideration within 30 days after the Effective Date. (The exact amount is described in the attached Third Amendment; portions of the exhibit are redacted.)

Why It Matters

• This is a material contractual update (Item 1.01) that adjusts the development and regulatory milestone schedule for the licensed program and creates an immediate payment obligation.
• For investors, the amendment affects the timeline for pre-clinical work and IND-related events that can influence the program’s progress and any milestone-driven cash flows or obligations between PMGC and MOA.
• The full terms and any redactions are included in the attached Third Amendment (Exhibit 10.1) filed with the 8-K.